Biosimilar developer Celltrion and Juno Pharmaceuticals announced that they have entered into a comarketing partnership for Celltrion’s trastuzumab biosimilar, Herzuma, and its rituximab biosimilar, Truxima, in the Australian market.
Biosimilar developer Celltrion and Juno Pharmaceuticals announced that they have entered into a comarketing partnership for Celltrion’s trastuzumab biosimilar, Herzuma, and its rituximab biosimilar, Truxima, in the Australian market.
Under the agreement, Celltrion will distribute the products in the Australian market, and Juno, a hospital supplier, will provide sales promotion and hospital contracting services to Australian hospital customers.
The new partnership comes shortly after Celltrion established its Australian branch in Sydney and subsequently joined Australia’s Generic and Biosimilar Medicines Association (GMBA), a group that represents generic and biosimilar manufacturers, suppliers, and exporters.
“At Celltrion Healthcare, our aim is to provide the best possible treatment options for patients and healthcare providers, and by connecting with the GBMA, we look forward to engaging positively to support the uptake of biosimilar medicines in Australia as a way to alleviate pressure on its national health system,” said Hyoung-Ki Kim, vice chairman and chief executive officer at Celltrion Healthcare, in a statement announcing the company’s new membership in the group.
The GBMA has taken an active role in providing education on biosimilars to stakeholders; in May of 2019, the group launched a new educational portal, funded by a grant by the Australian government, that provides tailored education to patients, prescribers, and pharmacists. Included in these materials is information on how some biosimilars—those that are “a-flagged”—can be substituted for their reference products at the point of dispensing.
Outside of Australia, Celltrion has been engaging in multiple other partnerships; in July of 2019, the company forged a joint venture, Vcell Healthcare Limited, together with Nan Fung Group to commercialize biosimilars in China. Last month, Celltrion also announced that it will contract with Swiss biologics maker Lonza to manufacture biosimilar infliximab CT-P13, sold as Remsima and Inflectra, in Singapore.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.